Literature DB >> 508579

Cell-cycle inhibition by misonidazole of human cells cultivated in vitro under aerobic conditions.

T Lindmo, E O Pettersen, E Wibe.   

Abstract

By means of flow cytometric recording of DNA histograms and counting of cells in synchronized populations, we have found that misonidazole (MIS) in clinically relevant concentrations induces cell-kinetic changes in human cells (NHIK 3025) cultivated in vitro under aerobic conditions. The effect seems to be a general lengthening of the cell cycle, affecting all phases. However, induction of this effect is phase-dependent, since only cells exposed to MIS during mitosis and/or early G1 will suffer significant cell-cycle prolongation. In exponentially growing populations this effect of MIS leads to a transient increase in the fraction of G1 cells and a corresponding decrease in the fraction of S cells. The possible significance of this effect for the clinical use of MIS is discussed.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 508579      PMCID: PMC2010116          DOI: 10.1038/bjc.1979.257

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  18 in total

1.  Further clinical experiences of a phase I study with the hypoxic cell radiosensitizer misonidazole.

Authors:  H D Kogelnik; J H Meyer; K Jentzsch; T Szepesi; K H Kärcher; E Maida; B Mamoli; P Wessely; F Zaunbauer
Journal:  Br J Cancer Suppl       Date:  1978-06

2.  The optimum regime for the administration of misonidazole and the establishment of multi-centre clinical trials.

Authors:  S Dische; M I Saunders; I R Flockhart
Journal:  Br J Cancer Suppl       Date:  1978-06

3.  Delay of cell cycle progression after X-irradiation of synchronized populations of human cells (NHIK 3025) in culture.

Authors:  T Lindmo; E O Pettersen
Journal:  Cell Tissue Kinet       Date:  1979-01

4.  Cell cycle characteristics of synchronized and asynchronous populations of human cells and effect of cooling of selected mitotic cells.

Authors:  E O Pettersen; O Bakke; T Lindmo; R Oftebro
Journal:  Cell Tissue Kinet       Date:  1977-11

5.  Differences in the toxicity and metabolism of the 2-nitroimidazole misonidazole (Ro-07-0582) in HeLa and Chinese hamster ovary cells.

Authors:  Y C Taylor; A M Rauth
Journal:  Cancer Res       Date:  1978-09       Impact factor: 12.701

6.  Cytological effects of 1-(2-nitro-1-imidazolyl)-3-methoxy-2-propanol (misonidazole) on hypoxic mammalian cells in vitro.

Authors:  C R Geard; S F Povlas; M B Astor; E J Hall
Journal:  Cancer Res       Date:  1978-03       Impact factor: 12.701

7.  Flow cytometric measurement of the polarization of fluorescence from intracellular fluorescein in mammalian cells.

Authors:  T Lindmo; H B Steen
Journal:  Biophys J       Date:  1977-05       Impact factor: 4.033

8.  Clonal growth in vitro of human cells with fibroblastic morphology; comparison of growth and genetic characteristics of single epithelioid and fibroblast-like cells from a variety of human organs.

Authors:  T T PUCK; S J CIECIURA; H W FISHER
Journal:  J Exp Med       Date:  1957-07-01       Impact factor: 14.307

9.  Split dose cytotoxic experiments with misonidazole.

Authors:  I J Stratford
Journal:  Br J Cancer       Date:  1978-07       Impact factor: 7.640

10.  Oncogenic transformation in vitro by the hypoxic cell sensitizer misonidazole.

Authors:  R C Miller; E J Hall
Journal:  Br J Cancer       Date:  1978-09       Impact factor: 7.640

View more
  3 in total

1.  Low concentrations of misonidazole counteract effects of extreme hypoxia on cells in S.

Authors:  E O Pettersen; T Lindmo
Journal:  Br J Cancer       Date:  1981-03       Impact factor: 7.640

2.  Growth delay in small EMT6 spheroids induced by cytotoxic drugs and its modification by misonidazole pretreatment under hypoxic conditions.

Authors:  P R Twentyman
Journal:  Br J Cancer       Date:  1982-04       Impact factor: 7.640

3.  Inhibition of cell-cycle progression by acute treatment with various degrees of hypoxia: modifications induced by low concentrations of misonidazole present during hypoxia.

Authors:  E O Pettersen; T Lindmo
Journal:  Br J Cancer       Date:  1983-12       Impact factor: 7.640

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.